| Potter, Jennifer S |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) |
|
|
| Completed | 2 | 333 | US | AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo | Aelis Farma, National Institute on Drug Abuse (NIDA) | Marijuana Abuse | 04/24 | 07/24 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
KIOS-I, NCT05859035: Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder |
|
|
| Active, not recruiting | N/A | 25 | US | KIOS Informational App, KIOS-I | Biomedical Development Corporation, The University of Texas Health Science Center at San Antonio, National Institute on Drug Abuse (NIDA) | Opioid-Related Disorders | 01/24 | 01/24 | | |
| Recruiting | N/A | 200 | US | KIOS App, KIOS, KIOS App education, KIOS education, Treatment as usual, TAU | The University of Texas Health Science Center at San Antonio, National Institute on Drug Abuse (NIDA), Biomedical Development Corporation | Opioid Use Disorder | 06/25 | 10/25 | | |
| Lu, Jun |
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
| Active, not recruiting | 3 | 120 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 01/24 | 02/25 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
GMCAII, NCT06221683: Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML |
|
|
| Recruiting | 2 | 500 | RoW | Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT | Children's Hospital of Soochow University | AML, Childhood, Acute Myeloid Leukemia | 12/28 | 12/29 | | |
NCT06316960: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation |
|
|
| Recruiting | 2 | 50 | RoW | Avapritinib, AYVAKIT, Azacitidine Injection, Azacitidine, Decitabine Injection, Decitabine, Idarubicin Hydrochloride, Idarubicine, Cytarabine, CYTOSAR, Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection | Children's Hospital of Soochow University | AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia, C-KIT Mutation | 03/26 | 03/27 | | |
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain |
|
|
| Active, not recruiting | 2 | 314 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain, Osteoarthritis, Knee | 08/24 | 12/24 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT05962450: Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy |
|
|
| Recruiting | 2 | 84 | RoW | iNKT Cells, Vα24+ T Cells, PD-1, Regorafenib | Beijing YouAn Hospital, Beijing Gene Key Life Technology Co., Ltd. | Hepatocellular Carcinoma | 08/25 | 08/25 | | |
NCT06456138: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | Trametinib, Anlotinib, Tislelizumab | Shanghai Chest Hospital, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis | KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor | 06/26 | 12/28 | | |
| Not yet recruiting | N/A | 264 | RoW | Acupuncture needles | Nanjing University of Traditional Chinese Medicine | Acute Respiratory Distress Syndrome, Sepsis | 06/26 | 12/26 | | |
NCT06777485: China Liver Cancer Clinical Registry Cohort Database |
|
|
| Recruiting | N/A | 10000 | RoW | Procedure/Surgery treatment, Anti-Tumor Drugs | Anhui Provincial Hospital | Liver Cancer | 01/35 | 01/35 | | |
NCT05449106: Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT |
|
|
| Recruiting | N/A | 200 | RoW | | Beijing Tiantan Hospital, Beijing Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Zhengzhou University | Brain Arteriovenous Malformations | 05/27 | 05/32 | | |
| Messina, John |
| Completed | 3 | 223 | Europe, US, RoW | OPN-375 | Optinose US Inc. | Chronic Rhinosinusitis | 05/22 | 05/22 | | |
NCT03747458: OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps |
|
|
| Recruiting | 3 | 120 | US | OPN-375 | Optinose US Inc. | Bilateral Nasal Polyposis | 03/26 | 03/26 | | |
| Soteres, Daniel |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 610 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, Japan, US, RoW | Ligelizumab 120 mg, Ligelizumab 240 mg | Novartis Pharmaceuticals | Food Allergy | 02/25 | 02/25 | | |
| Completed | 2 | 153 | Europe, Canada, US | TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Takeda | Celiac Disease | 11/24 | 11/24 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
| Active, not recruiting | 1/2 | 44 | Europe, US, RoW | Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331 | BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc. | Hereditary Angioedema, HAE | 11/28 | 11/28 | | |
| Tan, Ricardo |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 610 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Active, not recruiting | 3 | 641 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 60 | Canada, US | Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo | Apollo Therapeutics Ltd | Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic | 02/25 | 06/25 | | |
NCT06603220: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria |
|
|
| Recruiting | 2 | 30 | US | Oral EVO756 | Evommune, Inc. | Chronic Inducible Urticaria | 03/25 | 04/25 | | |
ASPIRE, NCT06504446: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough |
|
|
| Recruiting | 2 | 325 | Canada, US | NOC-110, taplucainium, Placebo | Nocion Therapeutics, Iqvia Pty Ltd | Refractory or Unexplained Chronic Cough | 11/25 | 11/25 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
| Geng, Bob |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 05/25 | 05/26 | | |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
| Finkel, Bruce D |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Rodicio, Ileana |
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma |
|
|
| Recruiting | 4 | 1136 | Canada, Japan, US, RoW | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists | GlaxoSmithKline | Asthma | 03/26 | 03/26 | | |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Talreja, Neetu |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
| Completed | 3 | 276 | Europe, Canada, Japan, US, RoW | Depemokimab (GSK3511294), Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nasal Polyps | 07/24 | 08/24 | | |
|
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT06603220: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria |
|
|
| Recruiting | 2 | 30 | US | Oral EVO756 | Evommune, Inc. | Chronic Inducible Urticaria | 03/25 | 04/25 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria |
|
|
| Completed | 1 | 33 | Europe, Canada, US | Oral EP262 | Escient Pharmaceuticals, Inc | Chronic Inducible Urticaria | 10/24 | 10/24 | | |
| Active, not recruiting | N/A | 718 | Europe, Canada, Japan, US | DUPIXENT®, dupilumab, REGN668, SAR231893 | Regeneron Pharmaceuticals, Sanofi | Asthma | 07/26 | 07/26 | | |
| Medina, Jorge A |
| Active, not recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 05/25 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Active, not recruiting | 2/3 | 225 | Canada, US | Piromelatine 20 mg, Neu-P11, Placebo | Neurim Pharmaceuticals Ltd., Syneos Health | Alzheimer's Disease | 06/25 | 06/25 | | |
POSCOL, NCT04663581: Comparison Between the Right Lateral Decubitus and the Left Lateral Decubitus as Starting Position in Colonoscopy |
|
|
| Recruiting | N/A | 167 | RoW | Left Sided Colonoscopy, Right Sided Colonoscopy | Sanitas University | Colonoscopy | 02/21 | 03/21 | | |
| Recruiting | N/A | 50 | Europe | ESP Block, Erector spinae Plane Block, Morphine injection, Intravenous opioid infusion analgesia and paracetamol | Hospital Clinic of Barcelona | Heart Valve Diseases, Postoperative Pain, Acute, Analgesia | 03/24 | 06/24 | | |
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. |
|
|
| Terminated | N/A | 715 | Europe, Japan, US, RoW | THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence | Philip Morris Products S.A. | COPD, Smoking, Tobacco Use | 09/24 | 09/24 | | |
| Gonzales, Stacy |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
| Hogue, Cheri |
NCT05248997: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis |
|
|
| Completed | 3 | 261 | US | rimegepant 75 mg ODT, Matching placebo | Pfizer, Biohaven Pharmaceutical Holding Company Ltd. | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | 03/24 | 04/24 | | |
| Recruiting | 2 | 75 | Europe, Canada, US, RoW | barzolvolimab, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Eosinophilic Esophagitis | 03/25 | 08/25 | | |
| Machado, Stacy |
| Active, not recruiting | 3 | 700 | Europe, Canada, US, RoW | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 04/25 | 04/25 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Completed | 2 | 50 | US | Allogeneic MSC, Placebo | Longeveron Inc., bioRASI, LLC | Mild Alzheimer's Disease | 09/23 | 09/23 | | |
| Hernandez, Erika |
| Active, not recruiting | 2 | 196 | Europe, US, RoW | barzolvolimab, CDX-0159, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Chronic Inducible Urticaria | 06/24 | 09/25 | | |
| Hanes, Angela |
| Active, not recruiting | 2 | 196 | Europe, US, RoW | barzolvolimab, CDX-0159, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Chronic Inducible Urticaria | 06/24 | 09/25 | | |
| Olivas, Karla |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
LIDS, NCT05276063: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 2/3 | 90 | Europe, Canada, US | Linsitinib, Placebo | Sling Therapeutics, Inc. | Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto | 10/24 | 09/26 | | |
| Onishi, Cheyenne |
| Active, not recruiting | 2 | 208 | Europe, US, RoW | barzolvolimab, CDX-0159, Matching Placebo | Celldex Therapeutics | Chronic Spontaneous Urticaria | 09/23 | 03/25 | | |
| Swanson, Elizabeth |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
| Gil, Stephanie |
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up |
|
|
| Recruiting | 3 | 100 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, placebo | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 11/25 | 02/32 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT06366750: A Study of Barzolvolimab in Patients with Prurigo Nodularis |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | barzolvolimab, Matching Placebo | Celldex Therapeutics | Prurigo Nodularis | 01/26 | 06/26 | | |
| Recruiting | 2 | 75 | Europe, Canada, US, RoW | barzolvolimab, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Eosinophilic Esophagitis | 03/25 | 08/25 | | |
| Bonora, Valentina |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Perez, Danelis Sanchez |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Cepero, Swanee |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Utter, Lauren |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 08/24 | 02/27 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
| Sackman, Shellie |
| Recruiting | 3 | 915 | Canada, US, RoW | barzolvolimab, Matching placebo | Celldex Therapeutics | Chronic Spontaneous Urticaria | 10/26 | 04/27 | | |
